Treatment of impaired glucose tolerance with acarbose and its effect on intima-media thickness: a substudy of the STOP-NIDDM trial (study to prevent non-insulin-dependent diabetes mellitus).

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
M Hanefeld

Abstract

To discuss the influence of glucose excursions on intima-media thickness (IMT) and the potential benefits of treatment to reduce or reverse its effects on cardiovascular risk. The findings in pertinent reported studies are reviewed, and the efficacy of various interventions for management of impaired glucose tolerance and type 2 diabetes in slowing the progression of IMT is analyzed. Considerable evidence from published epidemiologic studies provides compelling data regarding the association between postprandial and postchallenge glycemic excursions and cardiovascular risk. IMT has been shown to be a good surrogate marker for symptomatic and coronary atherosclerosis. Acarbose treatment in patients with impaired glucose tolerance has been shown to diminish the progression of IMT in comparison with placebo. In a study of repaglinide or glyburide therapy in patients with type 2 diabetes, a reduction in IMT was noted in the repaglinide group but not in the glyburide group at 1-year follow-up. Measurement of IMT allows direct observation of vascular damage attributable to postprandial and postchallenge hyperglycemia. It also provides a means for direct assessment of the effect of medications used for the control of glucose excursions.

References

May 1, 1994·Journal of Internal Medicine·G GeroulakosA G Shaper
Feb 1, 1996·Arteriosclerosis, Thrombosis, and Vascular Biology·C Bonithon-KoppP Ducimetière
Apr 10, 2004·Stroke; a Journal of Cerebral Circulation·Markolf HanefeldTheodora Temelkova-Kurktschiev
Jun 16, 2004·Circulation·Katherine EspositoUNKNOWN Campanian Postprandial Hyperglycemia Study Group

❮ Previous
Next ❯

Citations

Jul 1, 2011·Obesity Research & Clinical Practice·Ji Sun NamHyun Chul Lee
Feb 20, 2007·The American Journal of Cardiology·Gabriel I Uwaifo, Robert E Ratner
Nov 21, 2007·Angiology·Christopher Nielson, Richard M Fleming
Nov 24, 2011·Diabetes & Metabolism Journal·Bo Kyung Koo
Jan 15, 2009·Canadian Journal of Physiology and Pharmacology·D B McNamaraV A Fonseca
Dec 4, 2020·Pharmaceuticals·Malcolm J BorgTongzhi Wu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.